237 related articles for article (PubMed ID: 32268242)
1. Self-assembled polydopamine nanoparticles improve treatment in Parkinson's disease model mice and suppress dopamine-induced dyskinesia.
Vong LB; Sato Y; Chonpathompikunlert P; Tanasawet S; Hutamekalin P; Nagasaki Y
Acta Biomater; 2020 Jun; 109():220-228. PubMed ID: 32268242
[TBL] [Abstract][Full Text] [Related]
2. Targeting β-arrestin2 in the treatment of L-DOPA-induced dyskinesia in Parkinson's disease.
Urs NM; Bido S; Peterson SM; Daigle TL; Bass CE; Gainetdinov RR; Bezard E; Caron MG
Proc Natl Acad Sci U S A; 2015 May; 112(19):E2517-26. PubMed ID: 25918399
[TBL] [Abstract][Full Text] [Related]
3. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
[TBL] [Abstract][Full Text] [Related]
4. Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study.
Svenningsson P; Rosenblad C; Af Edholm Arvidsson K; Wictorin K; Keywood C; Shankar B; Lowe DA; Björklund A; Widner H
Brain; 2015 Apr; 138(Pt 4):963-73. PubMed ID: 25669730
[TBL] [Abstract][Full Text] [Related]
5. Differential Synaptic Remodeling by Dopamine in Direct and Indirect Striatal Projection Neurons in Pitx3
Suarez LM; Alberquilla S; García-Montes JR; Moratalla R
J Neurosci; 2018 Apr; 38(15):3619-3630. PubMed ID: 29483281
[TBL] [Abstract][Full Text] [Related]
6. Metformin Inhibits the Development of L-DOPA-Induced Dyskinesia in a Murine Model of Parkinson's Disease.
Ryu YK; Park HY; Go J; Choi DH; Kim YH; Hwang JH; Noh JR; Lee TG; Lee CH; Kim KS
Mol Neurobiol; 2018 Jul; 55(7):5715-5726. PubMed ID: 29039022
[TBL] [Abstract][Full Text] [Related]
7. Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia.
Ravenscroft P; Chalon S; Brotchie JM; Crossman AR
Exp Neurol; 2004 Jan; 185(1):36-46. PubMed ID: 14697317
[TBL] [Abstract][Full Text] [Related]
8. Effects of a combination treatment of KD5040 and
Ahn S; Song TJ; Park SU; Jeon S; Kim J; Oh JY; Jang J; Hong S; Song MA; Shin HS; Jung YR; Park HJ
BMC Complement Altern Med; 2017 Apr; 17(1):220. PubMed ID: 28424060
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Parkinson's disease: levodopa as the first choice.
Katzenschlager R; Lees AJ
J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
[TBL] [Abstract][Full Text] [Related]
11. Oleoylethanolamide reduces L-DOPA-induced dyskinesia via TRPV1 receptor in a mouse model of Parkinson´s disease.
González-Aparicio R; Moratalla R
Neurobiol Dis; 2014 Feb; 62():416-25. PubMed ID: 24140894
[TBL] [Abstract][Full Text] [Related]
12. [Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].
Damier P; Tremblay L; Féger J; Hirsch EC
Rev Neurol (Paris); 2000 Mar; 156(3):224-35. PubMed ID: 10740093
[TBL] [Abstract][Full Text] [Related]
13. DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease.
Johnston TH; Versi E; Howson PA; Ravenscroft P; Fox SH; Hill MP; Reidenberg BE; Corey R; Brotchie JM
Neuropharmacology; 2018 Mar; 131():116-127. PubMed ID: 29197517
[TBL] [Abstract][Full Text] [Related]
14. L-Dopa induced dyskinesias in Parkinsonian mice: Disease severity or L-Dopa history.
Shan L; Diaz O; Zhang Y; Ladenheim B; Cadet JL; Chiang YH; Olson L; Hoffer BJ; Bäckman CM
Brain Res; 2015 Aug; 1618():261-9. PubMed ID: 26086365
[TBL] [Abstract][Full Text] [Related]
15. In vivo characterization of a novel dopamine D3 receptor agonist to treat motor symptoms of Parkinson's disease.
Simms SL; Huettner DP; Kortagere S
Neuropharmacology; 2016 Jan; 100():106-15. PubMed ID: 25896768
[TBL] [Abstract][Full Text] [Related]
16. DopAmide: Novel, Water-Soluble, Slow-Release l-dihydroxyphenylalanine (l-DOPA) Precursor Moderates l-DOPA Conversion to Dopamine and Generates a Sustained Level of Dopamine at Dopaminergic Neurons.
Atlas D
CNS Neurosci Ther; 2016 Jun; 22(6):461-7. PubMed ID: 26861609
[TBL] [Abstract][Full Text] [Related]
17. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset.
Pearce RK; Banerji T; Jenner P; Marsden CD
Mov Disord; 1998 Mar; 13(2):234-41. PubMed ID: 9539335
[TBL] [Abstract][Full Text] [Related]
18. Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease.
Pinna A; Ko WK; Costa G; Tronci E; Fidalgo C; Simola N; Li Q; Tabrizi MA; Bezard E; Carta M; Morelli M
Mov Disord; 2016 Apr; 31(4):501-11. PubMed ID: 26871939
[TBL] [Abstract][Full Text] [Related]
19. Coadministration of hydroxysafflor yellow A with levodopa attenuates the dyskinesia.
Wang T; Duan SJ; Wang SY; Lu Y; Zhu Q; Wang LJ; Han B
Physiol Behav; 2015 Aug; 147():193-7. PubMed ID: 25914172
[TBL] [Abstract][Full Text] [Related]
20. Ondansetron, a highly selective 5-HT
Kwan C; Frouni I; Bédard D; Hamadjida A; Huot P
Eur J Pharmacol; 2020 Mar; 871():172914. PubMed ID: 31926127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
